glsi-100
Peptideexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Aug 11, 2022 (NCT05232916)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2ANTAGONIST
ERBB2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05232916 | Phase 3 | Aug 11, 2022 | Baylor University, Greenwich Biosciences |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Greenwich Biosciences | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1